Mavenclad and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
Determining the interaction of Mavenclad and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown. MANAGEMENT: Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. Cerner Multum, Inc. "Australian Product Information." O 0
Professional:GENERALLY AVOID: Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown.
MANAGEMENT: Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: cladribine
Brand name: Mavenclad, Leustatin
Synonyms: n.a.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Mavenclad-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Mavenclad-Omeclamox-Pak
- Mavenclad-Omega-3 Fatty Acid Capsules
- Mavenclad-Omega-3 Fatty Acids
- Mavenclad-Omega-3 polyunsaturated fatty acids
- Mavenclad-Omega-3-acid ethyl esters
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Mavik
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Mavyret
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Maxair
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Maxair Autohaler
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Maxalt
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Maxalt-MLT